The Winter Clinical Dermatology Conference brings dermatologists together to interact, learn, and network in the picturesque setting of Hawaii’s Big Island.
The Winter Clinical Dermatology Conference brings dermatologists together to interact, learn, and network in the picturesque setting of Hawaii’s Big Island.
Study results from a single center retrospective review suggests that the extent of hidradenitis suppurativa (HS) disease—rather than severity—plays a role in reducing the quality of life in patients with HS.
Study results from a single center retrospective review suggests that the extent of hidradenitis suppurativa (HS) disease—rather than severity—plays a role in reducing the quality of life in patients with HS.
It has been an impressive year in the field of dermatology. This annual article highlights some of the advances, discoveries, and recommendations that have made 2016 a great year in dermatology.
It has been an impressive year in the field of dermatology. This annual article highlights some of the advances, discoveries, and recommendations that have made 2016 a great year in dermatology.
The SDPA mentorship program is designed to give practicing dermatology PAs the opportunity to share the clinical and professional pearls they have garnered over the years.
The SDPA mentorship program is designed to give practicing dermatology PAs the opportunity to share the clinical and professional pearls they have garnered over the years.
Amor Khachemoune, MD, FAAD, FACMS; Sami K. Saikaly, BS
In this care, a 22-year-old female equestrian with a history of atopic dermatitis presented with mild to moderate pruritic, erythematous patches on her face, upper back, and fingers.
In this care, a 22-year-old female equestrian with a history of atopic dermatitis presented with mild to moderate pruritic, erythematous patches on her face, upper back, and fingers.
Shannon Humphrey, MD, FRCPC, FAAD, is an active clinical researcher with a focus on cutting-edge therapeutics in cosmetic dermatology, acne, and rosacea.
Shannon Humphrey, MD, FRCPC, FAAD, is an active clinical researcher with a focus on cutting-edge therapeutics in cosmetic dermatology, acne, and rosacea.
The Skin Cancer Foundation founder and president Perry Robins, MD, will retire from his position by the end of the year and Deborah S. Sarnoff, MD, will become president of the Foundation.
The Skin Cancer Foundation founder and president Perry Robins, MD, will retire from his position by the end of the year and Deborah S. Sarnoff, MD, will become president of the Foundation.
Over the past 15 years, we have seen remarkable changes in our ability to care for patients with moderate to severe psoriasis. We can take people with horrific psoriasis and get them basically clear—without having to wrap them in tar or make...
Over the past 15 years, we have seen remarkable changes in our ability to care for patients with moderate to severe psoriasis. We can take people with horrific psoriasis and get them basically clear—without having to wrap them in tar or make...
Climbing the mountain to get to dermatology residency is bone breaking enough, but what about the next apex, even more specialized training such as a Dermatopathology Fellowship?
Climbing the mountain to get to dermatology residency is bone breaking enough, but what about the next apex, even more specialized training such as a Dermatopathology Fellowship?
In a comparison of the mental health of patients with acne treated with isotretinoin vs oral antibiotics, which treatment group was found to experience more depressive symptoms and psychological distress?
In a comparison of the mental health of patients with acne treated with isotretinoin vs oral antibiotics, which treatment group was found to experience more depressive symptoms and psychological distress?
Alopecia areata (AA) is an autoimmune disease characterized by sudden hair loss that can occur in patches and may lead to complete scalp and body hair loss. JAK inhibitors have emerged as a groundbreaking treatment for severe AA.
Alopecia areata (AA) is an autoimmune disease characterized by sudden hair loss that can occur in patches and may lead to complete scalp and body hair loss. JAK inhibitors have emerged as a groundbreaking treatment for severe AA.
What proportion of children aged 6 to 11 years with severe atopic dermatitis receiving dupilumab achieved a height increase of at least 5 percentile points after 4 months of treatment?
What proportion of children aged 6 to 11 years with severe atopic dermatitis receiving dupilumab achieved a height increase of at least 5 percentile points after 4 months of treatment?
Evaluate advanced clinical reasoning in targeted treatment selection, unexpected therapeutic responses, and the challenges of precision medicine in inflammatory dermatology.
Evaluate advanced clinical reasoning in targeted treatment selection, unexpected therapeutic responses, and the challenges of precision medicine in inflammatory dermatology.
Challenge your understanding of inflammatory feedback mechanisms, neuronal sensitization, and the complex cellular interactions involved in chronic dermatologic disease.
Challenge your understanding of inflammatory feedback mechanisms, neuronal sensitization, and the complex cellular interactions involved in chronic dermatologic disease.
Test your clinical understanding of inflammatory disease classification, overlapping immune pathways, and the evolving role of type 2 inflammation in dermatology.
Test your clinical understanding of inflammatory disease classification, overlapping immune pathways, and the evolving role of type 2 inflammation in dermatology.
Challenge your understanding of treatment sequencing, biologic failure, JAK inhibitor escalation, and future biomarker-driven approaches in inflammatory dermatology.
Challenge your understanding of treatment sequencing, biologic failure, JAK inhibitor escalation, and future biomarker-driven approaches in inflammatory dermatology.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...